Publicaciones (55) Publicaciones de ANA BLAS GARCIA

2024

  1. Benefits of rilpivirine for liver stiffness in HIV/HCV-coinfected patients

    Enfermedades Infecciosas y Microbiologia Clinica, Vol. 42, Núm. 2, pp. 74-79

  2. Integrated transcriptomic landscape of the effect of anti-steatotic treatments in high-fat diet mouse models of non-alcoholic fatty liver disease

    Journal of Pathology, Vol. 262, Núm. 3, pp. 377-389

  3. Interference with mitochondrial function as part of the antifibrogenic effect of Rilpivirine: A step towards novel targets in hepatic stellate cell activation

    Biomedicine and Pharmacotherapy, Vol. 178

  4. Proceedings of the 5th Meeting of Translational Hepatology, organized by the Spanish Association for the Study of the Liver (AEEH)

    Gastroenterologia y Hepatologia

  5. Rilpivirine Activates STAT1 in Non-Parenchymal Cells to Regulate Liver Injury in People Living with HIV and MASLD

    Biomedicines, Vol. 12, Núm. 7

2023

  1. Anti-inflammatory and immunomodulating effects of rilpivirine: Relevance for the therapeutics of chronic liver disease

    Biomedicine and Pharmacotherapy, Vol. 167

  2. Novel Therapeutic Approaches to Liver Fibrosis Based on Targeting Oxidative Stress

    Antioxidants, Vol. 12, Núm. 8

2022

  1. Down-Regulation of the Longevity-Associated Protein SIRT1 in Peripheral Blood Mononuclear Cells of Treated HIV Patients

    Cells, Vol. 11, Núm. 3

  2. Editorial: Advances in non-alcoholic fatty liver disease therapeutics: Pathogenic mechanisms and targets

    Frontiers in Pharmacology

  3. Implication of autophagy in the antifibrogenic effect of Rilpivirine: when more is less

    Cell Death and Disease, Vol. 13, Núm. 4

  4. Macrophages Modulate Hepatic Injury Involving NLRP3 Inflammasome: The Example of Efavirenz

    Biomedicines, Vol. 10, Núm. 1

  5. Metabolic-associated fatty liver disease: From simple steatosis toward liver cirrhosis and potential complications. Proceedings of the Third Translational Hepatology Meeting, organized by the Spanish Association for the Study of the Liver (AEEH)

    Gastroenterologia y Hepatologia, Vol. 45, Núm. 9, pp. 724-734

2021

  1. Apoptosis of Hepatocytes: Relevance for HIV-Infected Patients under Treatment

    Cells, Vol. 10, Núm. 2

  2. Guidelines for the use and interpretation of assays for monitoring autophagy (4th edition)1

    Autophagy, Vol. 17, Núm. 1, pp. 1-382

  3. NNRTI and Liver Damage: Evidence of Their Association and the Mechanisms Involved

    Cells, Vol. 10, Núm. 7

  4. Understanding the implication of autophagy in the activation of hepatic stellate cells in liver fibrosis: are we there yet?

    Journal of Pathology, Vol. 254, Núm. 3, pp. 216-228

2020

  1. Differential Effects of Biologics on Psoriasis-Related Vascular Inflammation and Risk of Thrombosis

    Journal of Investigative Dermatology, Vol. 140, Núm. 11, pp. 2294-2298.e6

  2. Rilpivirine attenuates liver fibrosis through selective STAT1-mediated apoptosis in hepatic stellate cells

    Gut, Vol. 69, Núm. 5, pp. 920-932

  3. p53 and p53-related mediators PAI-1 and IGFBP-3 are downregulated in peripheral blood mononuclear cells of HIV-patients exposed to non-nucleoside reverse transcriptase inhibitors

    Antiviral Research, Vol. 178

2019

  1. Mitophagy in human astrocytes treated with the antiretroviral drug Efavirenz: Lack of evidence or evidence of the lack

    Antiviral Research, Vol. 168, pp. 36-50